"use strict";(self.webpackChunkgenomics_docusaurus_new=self.webpackChunkgenomics_docusaurus_new||[]).push([[80],{6579:(e,n,s)=>{s.r(n),s.d(n,{assets:()=>l,contentTitle:()=>a,default:()=>h,frontMatter:()=>o,metadata:()=>i,toc:()=>c});const i=JSON.parse('{"id":"oncology-europe/nsclc_markers","title":"Actionable Biomarkers & CDx Scope","description":"Core Predictive Biomarkers in Advanced NSCLC","source":"@site/docs/oncology-europe/nsclc_markers.md","sourceDirName":"oncology-europe","slug":"/oncology-europe/nsclc_markers","permalink":"/datasolutions/oncology-europe/nsclc_markers","draft":false,"unlisted":false,"tags":[],"version":"current","sidebarPosition":4,"frontMatter":{"title":"Actionable Biomarkers & CDx Scope","sidebar_position":4,"hide_title":true},"sidebar":"docsSidebar","previous":{"title":"NSCLC as Case Study","permalink":"/datasolutions/oncology-europe/nsclc_intro"},"next":{"title":"Platform Deployment & Testing Models","permalink":"/datasolutions/oncology-europe/platforms_overview"}}');var r=s(4848),t=s(8453);s(6025);const o={title:"Actionable Biomarkers & CDx Scope",sidebar_position:4,hide_title:!0},a=void 0,l={},c=[{value:"Core Predictive Biomarkers in Advanced NSCLC",id:"core-predictive-biomarkers-in-advanced-nsclc",level:2},{value:"Orthogonal biomarkers and non-NGS assays",id:"orthogonal-biomarkers-and-non-ngs-assays",level:3},{value:"Implications for CDx assay scope",id:"implications-for-cdx-assay-scope",level:3}];function d(e){const n={br:"br",h2:"h2",h3:"h3",hr:"hr",li:"li",p:"p",strong:"strong",ul:"ul",...(0,t.R)(),...e.components},{Details:s}=n;return s||function(e,n){throw new Error("Expected "+(n?"component":"object")+" `"+e+"` to be defined: you likely forgot to import, pass, or provide it.")}("Details",!0),(0,r.jsxs)(r.Fragment,{children:[(0,r.jsx)(n.h2,{id:"core-predictive-biomarkers-in-advanced-nsclc",children:"Core Predictive Biomarkers in Advanced NSCLC"}),"\n",(0,r.jsx)(n.hr,{}),"\n",(0,r.jsx)("div",{style:{textAlign:"justify"},children:(0,r.jsx)(n.p,{children:"Current clinical practice guidelines converge on a defined group of predictive biomarkers that are routinely assessed in patients with advanced NSCLC to inform initial and subsequent treatment decisions:"})}),"\n",(0,r.jsx)("br",{}),"\n",(0,r.jsxs)(s,{style:{backgroundColor:"#f5f9ff",border:"1px solid #c9ddff",borderRadius:"10px",padding:"1rem 1.2rem"},children:[(0,r.jsx)("summary",{style:{fontWeight:"600",cursor:"pointer"},children:(0,r.jsx)(n.p,{children:"Core Actionable Biomarkers in NSCLC"})}),(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:["\n",(0,r.jsxs)(n.p,{children:[(0,r.jsx)(n.strong,{children:"EGFR"}),(0,r.jsx)(n.br,{}),"\n","Activating mutations and resistance variants guiding tyrosine kinase inhibitor (TKI) therapy"]}),"\n"]}),"\n",(0,r.jsxs)(n.li,{children:["\n",(0,r.jsxs)(n.p,{children:[(0,r.jsx)(n.strong,{children:"ALK"}),(0,r.jsx)(n.br,{}),"\n","Gene fusions associated with sensitivity to ALK-targeted inhibitors"]}),"\n"]}),"\n",(0,r.jsxs)(n.li,{children:["\n",(0,r.jsxs)(n.p,{children:[(0,r.jsx)(n.strong,{children:"ROS1"}),(0,r.jsx)(n.br,{}),"\n","Gene fusions with established targeted treatment options"]}),"\n"]}),"\n",(0,r.jsxs)(n.li,{children:["\n",(0,r.jsxs)(n.p,{children:[(0,r.jsx)(n.strong,{children:"BRAF"}),(0,r.jsx)(n.br,{}),"\n","Activating mutations, most notably p.V600E"]}),"\n"]}),"\n",(0,r.jsxs)(n.li,{children:["\n",(0,r.jsxs)(n.p,{children:[(0,r.jsx)(n.strong,{children:"KRAS"}),(0,r.jsx)(n.br,{}),"\n","With specific therapeutic relevance for the p.G12C mutation"]}),"\n"]}),"\n",(0,r.jsxs)(n.li,{children:["\n",(0,r.jsxs)(n.p,{children:[(0,r.jsx)(n.strong,{children:"MET exon 14 skipping"}),(0,r.jsx)(n.br,{}),"\n","Splice alterations conferring sensitivity to MET-directed therapies"]}),"\n"]}),"\n",(0,r.jsxs)(n.li,{children:["\n",(0,r.jsxs)(n.p,{children:[(0,r.jsx)(n.strong,{children:"RET"}),(0,r.jsx)(n.br,{}),"\n","Gene fusions associated with targeted inhibitor response"]}),"\n"]}),"\n",(0,r.jsxs)(n.li,{children:["\n",(0,r.jsxs)(n.p,{children:[(0,r.jsx)(n.strong,{children:"NTRK1/2/3"}),(0,r.jsx)(n.br,{}),"\n","Rare gene fusions with tumour-agnostic therapeutic implications"]}),"\n"]}),"\n"]})]}),"\n",(0,r.jsx)("br",{}),"\n",(0,r.jsx)("div",{style:{textAlign:"justify"},children:(0,r.jsxs)(n.p,{children:["Although the prevalence of several of these alterations is low, ",(0,r.jsx)(n.strong,{children:"missing them can mean overlooking highly effective targeted treatments"}),". For this reason, molecular testing in NSCLC should be designed to ",(0,r.jsx)(n.strong,{children:"check broadly across many alterations"}),", rather than focusing only on the most common ones."]})}),"\n",(0,r.jsx)(n.h3,{id:"orthogonal-biomarkers-and-non-ngs-assays",children:"Orthogonal biomarkers and non-NGS assays"}),"\n",(0,r.jsx)(n.hr,{}),"\n",(0,r.jsxs)("div",{style:{textAlign:"justify"},children:[(0,r.jsxs)(n.p,{children:["In parallel with genomic profiling, ",(0,r.jsx)(n.strong,{children:"PD-L1 expression"})," is routinely assessed by immunohistochemistry (IHC) to guide immunotherapy decisions."]}),(0,r.jsx)(n.p,{children:"PD-L1 testing is operationally inseparable from the NSCLC CDx workflow, as molecular and immunotherapy stratification are performed together during diagnosis."})]}),"\n",(0,r.jsx)(n.h3,{id:"implications-for-cdx-assay-scope",children:"Implications for CDx assay scope"}),"\n",(0,r.jsx)(n.hr,{}),"\n",(0,r.jsxs)("div",{style:{textAlign:"justify"},children:[(0,r.jsx)(n.p,{children:"The diversity of genetic alterations that must be assessed in NSCLC directly shapes how diagnostic assays are designed:"}),(0,r.jsxs)(n.ul,{children:["\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Single-gene tests"})," cannot efficiently capture the full range of actionable alterations"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"DNA only approaches"})," may miss clinically relevant gene fusions and splice events"]}),"\n",(0,r.jsxs)(n.li,{children:[(0,r.jsx)(n.strong,{children:"Comprehensive testing"})," must balance coverage, sensitivity, tissue usage, and turnaround time"]}),"\n"]}),(0,r.jsxs)(n.p,{children:["As a result, ",(0,r.jsx)(n.strong,{children:"NSCLC requires more complex diagnostic workflows"}),", and testing increasingly relies on ",(0,r.jsx)(n.strong,{children:"integrated, multi-target sequencing strategies"})," rather than isolated assays."]})]})]})}function h(e={}){const{wrapper:n}={...(0,t.R)(),...e.components};return n?(0,r.jsx)(n,{...e,children:(0,r.jsx)(d,{...e})}):d(e)}},8453:(e,n,s)=>{s.d(n,{R:()=>o,x:()=>a});var i=s(6540);const r={},t=i.createContext(r);function o(e){const n=i.useContext(t);return i.useMemo((function(){return"function"==typeof e?e(n):{...n,...e}}),[n,e])}function a(e){let n;return n=e.disableParentContext?"function"==typeof e.components?e.components(r):e.components||r:o(e.components),i.createElement(t.Provider,{value:n},e.children)}}}]);